{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:17:29Z","timestamp":1793654249629,"version":"4.5.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The firstMIND trial (NCT04134936) evaluated the safety and efficacy of adding lenalidomide to R-CHOP+tafasitamab in the first-line treatment settings of patients with diffuse large B-cell lymphoma. To address response dynamics and the impact of measurable residual disease (MRD), we analyzed prospectively collected plasma samples from 56 study patients using the EuroClonality immunoglobulin gene (IG)-NGS assay. At baseline, disease-related clonotypes were identified in 50\/56 (89%) patients by IG-NGS in cell-free (cf)DNA and\/or FFPE samples. MRD markers were successfully identified in 49\/52 (94%) cfDNA samples and 35\/41 (85%) FFPE samples. Baseline cfDNA and circulating tumor (ct)DNA levels correlated with preclinical risk factors, and high cfDNA levels \u22653.35 log\n                    <jats:sub>10<\/jats:sub>\n                    hGE\/ml plasma were significantly associated with poor progression-free survival (PFS) (hazard ratio (HR): 3.1). ctDNA clearance was rapid with 52% of patients MRD-negative at C2D1, 83% patients at C4D1, and 82% patients after finishing six 21-day cycles (end of treatment (EOT)) and a sustained treatment response (93% MRD negative) six months after EOT. ctDNA detection was associated with worse PFS outcomes at C2D1 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039, HR:4.51, 95%Cl:0.93\u201321.74), C4D1 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.07, HR:3.34, 95%Cl:0.83\u201313.48) and EOT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01, HR:6.38, 95%Cl:1.27\u201332.01) and inferior overall survival at these time points. In PET-positive patients, ctDNA-MRD had a higher specificity rendering PET\/CT more precisely.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02759-4","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:37:52Z","timestamp":1761554272000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/\u2212 lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9461","authenticated-orcid":false,"given":"Mouhamad","family":"Khouja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Kehden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Versteegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Nakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Schilhabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Darzentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9260-8340","authenticated-orcid":false,"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EuroClonality-NGS Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2759_CR1","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"JO Armitage","year":"1997","unstructured":"Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89:3909\u201318.","journal-title":"Blood"},{"key":"2759_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"2759_CR3","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"2759_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94:604\u201316.","journal-title":"Am J Hematol"},{"key":"2759_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","volume":"5","author":"L Kostakoglu","year":"2021","unstructured":"Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, et al. End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021;5:1283\u201390.","journal-title":"Blood Adv"},{"key":"2759_CR6","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679\u201387.","journal-title":"Blood"},{"key":"2759_CR7","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood.2021012852","volume":"139","author":"L Meriranta","year":"2022","unstructured":"Meriranta L, Alkodsi A, Pasanen A, Lepist\u00f6 M, Mapar P, Blaker YN, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139:1863\u201377.","journal-title":"Blood"},{"key":"2759_CR8","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129:1947\u201357.","journal-title":"Blood"},{"key":"2759_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1182\/blood.2023020637","volume":"142","author":"D Belada","year":"2023","unstructured":"Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, Andr\u00e9 M, Persona EP, et al. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 2023;142:1348\u201358.","journal-title":"Blood"},{"key":"2759_CR10","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1182\/blood-2022-163160","volume":"140","author":"GS Nowakowski","year":"2022","unstructured":"Nowakowski GS, Duell J, Kopeckova K, Trneny M, Pott C, Khouja M, et al. First-mind: final analysis from a Phase Ib, open-label, randomized study to assess safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. Blood. 2022;140:3731\u20133.","journal-title":"Blood"},{"key":"2759_CR11","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1182\/blood-2021-148354","volume":"138","author":"D Belada","year":"2021","unstructured":"Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, Andr\u00e9 M, P\u00e9rez Persona E, et al. First-mind: primary analysis from a phase Ib, open-label, randomized study to assess safety of tafasitamab or Tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. Blood. 2021;138:3556.","journal-title":"Blood"},{"key":"2759_CR12","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1007\/s00216-014-7835-3","volume":"406","author":"AS Devonshire","year":"2014","unstructured":"Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406:6499\u2013512.","journal-title":"Anal Bioanal Chem"},{"key":"2759_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-2115-8_7","volume":"2453","author":"C Pott","year":"2022","unstructured":"Pott C, Kotrova M, Darzentas N, Br\u00fcggemann M, Khouja M. cfDNA-Based NGS IG analysis in lymphoma. Methods Mol Biol. 2022;2453:101\u201317.","journal-title":"Methods Mol Biol"},{"key":"2759_CR14","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","volume":"33","author":"M Br\u00fcggemann","year":"2019","unstructured":"Br\u00fcggemann M, Kotrov\u00e1 M, Knecht H, Bartram J, Boudjogrha M, Bystry V, et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 2019;33:2241\u201353.","journal-title":"Leukemia"},{"key":"2759_CR15","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41375-019-0499-4","volume":"33","author":"H Knecht","year":"2019","unstructured":"Knecht H, Reigl T, Kotrov\u00e1 M, Appelt F, Stewart P, Bystry V, et al. Quality control and quantification in IG\/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia. 2019;33:2254\u201365.","journal-title":"Leukemia"},{"key":"2759_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/bioinformatics\/btw634","volume":"33","author":"V Bystry","year":"2017","unstructured":"Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Grioni A, et al. ARResT\/Interrogate: an interactive immunoprofiler for IG\/TR NGS data. Bioinformatics. 2017;33:435\u20137.","journal-title":"Bioinformatics"},{"key":"2759_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000543","volume":"5","author":"I Della Starza","year":"2021","unstructured":"Della Starza I, Nunes V, Lovisa F, Silvestri D, Cavalli M, Garofalo A, et al. Droplet digital PCR improves IG-\/TR-based MRD risk definition in childhood B-cell precursor acute lymphoblastic leukemia. HemaSphere. 2021;5:1\u20137.","journal-title":"HemaSphere"},{"key":"2759_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000347","volume":"4","author":"D Drandi","year":"2020","unstructured":"Drandi D, Alcantara M, Benmaad I, S\u00f6hlbrandt A, Lhermitte L, Zaccaria G, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL network. HemaSphere. 2020;4:e347.","journal-title":"HemaSphere"},{"key":"2759_CR19","doi-asserted-by":"crossref","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. In: Methods in Molecular Biology. 2019, pp 199\u2013228.","DOI":"10.1007\/978-1-4939-9151-8_9"},{"key":"2759_CR20","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig S, Macaulay CW, Kurtz DM, D\u00fchrsen U, H\u00fcttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605\u201316.","journal-title":"J Clin Oncol"},{"key":"2759_CR21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1182\/bloodadvances.2021006415","volume":"6","author":"AF Herrera","year":"2022","unstructured":"Herrera AF, Tracy S, Croft B, Opat S, Ray J, Lovejoy AF, et al. Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022;6:1651\u201360.","journal-title":"Blood Adv"},{"key":"2759_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","volume":"178","author":"DM Kurtz","year":"2019","unstructured":"Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019;178:699\u2013713.","journal-title":"Cell"},{"key":"2759_CR23","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845\u201353.","journal-title":"J Clin Oncol"},{"key":"2759_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1182\/blood-2023-180007","volume":"142","author":"M Roschewski","year":"2023","unstructured":"Roschewski M, Lindenberg L, Mena E, Lakhotia R, Melani C, Steinberg SM, et al. End-of-treatment response assessment after frontline therapy for aggressive B-Cell lymphoma: landmark comparison of a singular PET\/CT scan versus ultrasensitive circulating tumor DNA. Blood. 2023;142:192.","journal-title":"Blood"},{"key":"2759_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","volume":"3","author":"M Roschewski","year":"2022","unstructured":"Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Circulating tumor DNA in lymphoma: principles and future directions. Blood Cancer Discov. 2022;3:5\u201315.","journal-title":"Blood Cancer Discov"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02759-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:03:30Z","timestamp":1767985410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02759-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2759"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02759-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MK, BK, TV, PN, AS, and ND: nothing to declare. DB, CK and SW: Employees of MorphoSys, MB: Advisory Board: Incyte, Amgen, Speaker: BD, Janssen, Pfizer, Amgen, research funding: Amgen., CB: Consultancy: Astellas, BMS, AstraZeneca, Amgen, Jazz Pharmaceuticals, Gilead, and Janssen., GN: Consultancy: AbbVie, ADC Therapeutics, Bantam Pharmaceutical LLC, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Curis, Debiopharm, F Hoffmann-La Roche Limited, Fate Therapeutics, Genentech, Genmab, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys AG, Regeneron, Roche, Ryvu Therapeutics, Seagen, Selvita Inc, TG Therapeutics, Urogen., DB: Consultancy, Research support: Roche, Seattle Genetics, Takeda, Morphosys, Abbvie, Gilead Sciences, BMS, Beigene, Astra Zeneca, Sobi, Regeneron., CP: research Funding: Roche, MorphoSys, Honoraria: Lilly, Novartis, Kite, Gilead, Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was led according to the Declaration of Helsinki. All patients gave their written informed consent after have been informed about the purpose and investigational nature of the trial. Prior to initiation, the clinical trial including molecular analysis received approval by the respective ethics committee of each participating country: University of Vienna, Austria, Erasmus Hospital, Belgium, University Hospital Hradec Kralove, Czech Republic, University of Rouen, France, University of G\u00f6ttingen, Germany, Research Ethics committee of Sabadell, Spain, Western Institutional Review Board, Mayo Clinic, Advarra institutional Review Board and US Oncology Inc. Institutional Review Board, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}